Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease, which in the majority of patients progresses to liver transplantation or death. To date, no medical treatment has been proven to be of benefit, although ursodeoxycholic acid is widely used. The etiopathogenesis of PSC is unclear, although it is associated with inflammatory bowel disease. Various hypotheses have been suggested, which have led to different therapeutic strategies. Recent studies have suggested that the microbiome may play a role in PSC, raising the possibility of efficacy of antibiotics and fecal microbiota transplantation. Gut-homing T cells may be important in the pathogenesis of PSC, and several agents are in development, targeting various receptors, integrins, and ligands on this pathway, including VAP-1, MAdCAM-1, α4β7, and CCR9. Nuclear receptor agonists such as obeticholic acid and fibrates hold promise, as do other therapies that alter bile acid composition such as norUDCA. Antifibrotic agents such as Loxl2 inhibitors are also being assessed. In conclusion, it is likely that an effective drug therapy for PSC will become available over the next decade.

Original publication

DOI

10.1055/s-0035-1571274

Type

Journal article

Journal

Semin Liver Dis

Publication Date

02/2016

Volume

36

Pages

5 - 14

Keywords

Animals, Anti-Bacterial Agents, Bile Acids and Salts, Cholagogues and Choleretics, Cholangitis, Sclerosing, Endoscopy, Gastrointestinal, Fecal Microbiota Transplantation, Gastrointestinal Microbiome, Humans, Liver, Liver Cirrhosis, Biliary, Molecular Targeted Therapy, Risk Factors, Signal Transduction, Treatment Outcome